Articles

Poll

Podcasts

Slideshows

Videos

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

A pair of experts discuss their research on trends in the use of GLP-1 RAs in patients with IBD as well as their safety and efficacy in this patient population.

New Research Supports GLP-1 RA Use in IBD for Weight Loss, Disease Control

Horst explains the importance of addressing depression and anxiety in patients with IBD and steps clinicians can take to support their patients’ mental health.

Managing Mental Health in Patients with IBD, with Sara Horst, MD, MPH

Subgroup analysis findings highlight duvakitug’s efficacy and tolerability across different levels of inflammation in ulcerative colitis.

RELIEVE-UCCD: Duvakitug Improves Clinical, Endoscopic Outcomes in UC Subgroups

Biomarker-informed molecular guidance led to greater achievement of disease control compared with standard “best care” for IBD anti-TNF therapy.

GUIDE-IBD: Biomarker-Informed Therapy Decisions Improve Outcomes with Anti-TNF

Long-term childhood outcomes were comparable in biologic-exposed and unexposed infants born to mothers with inflammatory bowel disease.

IBD Biologic Use During Pregnancy Does Not Impact Long-Term Infant Outcomes

Our Q1 recap for gastroenterology spotlights regulatory updates, clinical trial data, and new research and guidance about colorectal cancer screening.

Q1 2025 Recap: Gastroenterology News and Updates

Investigators encourage further study of treatment and therapy methods for childhood IBD.

Trend Indicated Between Anemia and Childhood Inflammatory Bowel Disease

The March 2025 month in review spotlights an RX Review about USMSTF guidance on bowel prep for colonoscopy, an FDA approval, and clinical trial updates.

Gastroenterology Month in Review: March 2025

Our top 5 headlines featured new migraine guidelines, the benefit of automated insulin delivery for type 2 diabetes, and 3 key FDA decisions.

The HCPFive: Top News for Healthcare Providers from the Week of 03/16

The approval for moderately to severely active Crohn disease marks the fourth indication for Johnson and Johnson's IL-23 inhibitor.

FDA Approves Guselkumab (Tremfya) For Crohn Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.